New insights to structure and immunological features of Leishmania lipophosphoglycan3.

Authors :: Hosseini M
Haji-Fatahaliha M
Miahipour A
Yousefi M
Source :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2017 Nov; Vol. 95, pp. 1369-1374. Date of Electronic Publication: 2017 Sep 21.
Publication Year :: 2017
Abstract: Leishmaniasis is a major public infectious disease caused by the genus Leishmania. No effective drug or vaccination strategy for leishmaniasis has been designed yet. Several intracellular Leishmania antigens have been recognized to serve in vaccination, ensuring long-lasting protection against Leishmania infection. Lipophosphoglican 3 (LPG3) as a member of the heat shock protein 90 family involves in the synthesis of lipophosphoglycan (LPG) and implicates in parasite virulence. Regarding the immunological properties of LPG3 particularly its N-terminal fragment, it would be considered as a favourable adjuvant in Leishmania vaccination.<br /> (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)

Subjects :: Adaptive Immunity
Animals
Heat-Shock Proteins metabolism
Humans
Immunity, Innate
Vaccination
Glycosphingolipids chemistry
Glycosphingolipids immunology
Leishmania chemistry
Leishmania immunology

Full Text Access

Tools